INTRODUCTION
In vitro-generated, stem cell-derived cerebral organoids closely mimic characteristic human fetal neurodevelopment in vivo while providing unlimited brain tissue comprising specific cell populations such as neuronal progenitors, neurons, and astrocytes. This three-dimensional tissue allows for direct testing of brain development and modeling of complex human neurological disorders such as hereditary microcephaly, autism spectrum disorders, and Alzheimer's disease (Choi et al., 2014; Lancaster et al., 2013; Mariani et al., 2015) . Brain organoids have also proven useful for dissecting the general impact of viral infections on brain development. For example, Zika virus infection of cerebral organoids confirmed the neurotropic nature of the virus and provided rapid confirmation of the causal link between prenatal Zika virus infection and congenital microcephaly (Garcez et al., 2016) . However, with the creation of more-complex multilayered tissue models comes the challenge of developing assays that can translate complex experimental starting conditions into useful data outputs. Possibilities to reduce this complexity include the use of organoids confined to specific brain regions (Qian et al., 2016) or microdissection of certain cerebral organoid anatomy combined with single-cell RNA sequencing (Camp et al., 2015) . Nevertheless, a satisfying approach to study the effects of virus infection or other treatments in distinct cell populations of organoids has been lacking. We describe a protocol to isolate neural progenitors, astrocytes, and neurons from virus-infected cerebral organoids, validated for downstream epigenetic and gene expression assays (Janssens et al., 2018) . This article outlines in detail how to prepare Zika and single-cycle lentiviral reporter viruses, prepare cerebral organoid cultures for viral infection, identify neuronal populations, and subsequently isolate infected and non-infected neural progenitor cells, neurons, and astrocytes suitable for downstream manipulations such as RNA and DNA extraction.
CAUTION: Manipulations of virus-containing cultures must be carried out in biological safety cabinets with appropriate personal protective equipment (PPE). Infectious waste must be collected and disposed of according to the correct biosafety level (BSL) guidelines.
BASIC PROTOCOL 1

GENERATION OF 2D CEREBRAL ORGANOID CULTURES FOR OPTIMAL VIRAL INFECTION
This protocol describes the generation of a 2D culture that is optimal for ample viral infection while maintaining the original cell types and cell interactions typical of cerebral organoids (Fig. 1) . The successful isolation of virus-infected cells from cerebral organoids strongly correlates with the initial infection rate. Fluorescence-activated cell sorting (FACS) requires that a large enough portion of cells be separated from background noise, and downstream applications are limited by minimal material input. While developing this protocol, low infection rates were experienced when infecting mature cerebral organoids as a whole. Vibratome slicing and culturing of the cerebral organoid as 500-µm-thick slices elevated infection rates to some extent by increasing surface exposure to the virus (Fig. 1C ). Nevertheless, switching to twodimensional culture conditions was deemed necessary to reach satisfactory infection rates.
This protocol has been optimized for cerebral organoids generated according to Lancaster et al. (2013) , but is expected to be adaptable to alternative neural organoid growing methods. A step-by-step protocol for generation of cerebral organoids (Lancaster & Knoblich, 2014) describes in detail the consecutive phases of making embryonic bodies, inducing neural fate, and establishing a threedimensional culture. In our experience, H9 (WAO9) human embryonic stem cells (hESCs) are most suitable for generation of cerebral organoids containing high levels of brain tissues, while satisfactory results have been obtained when using H1 (WA01) cells. Janssens et al.
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Current Protocols in Stem Cell Biology 2. Add one Matrigel aliquot to 12 ml ice-cold DMEM/F12 in a 15-ml polypropylene centrifuge tube, dissolve, and immediately add 1 ml per well to two 6-well flatbottom plates.
Materials
3. Incubate plates for 1 hr at room temperature.
4. Add 1 extra ml DMEM/F12 per well and store in a 37°C incubator for up to 1 week.
Collect and dissociate organoids 5. Pipet 2-3 mature organoids ( Fig. 1B) per well into a 24-well plate using 25-ml serological pipets.
6. Remove excess medium that was transferred with the organoids, then add 0.5 ml Accutase per well and place in the 37°C incubator for 3-5 min.
7. Initiate dissociation by pipetting the organoid/Accutase mixture up and down several times using low-binding 1000-µl filter tips and incubate for another 3-5 min at 37°C. Do not exceed 10 min of exposure to undiluted Accutase.
8. Further dissociate the organoids into little chunks by pipetting up and down several more times and immediately transfer the solution to a 50-ml tube containing at least 5 ml cerebral organoid medium per 0.5 ml Accutase.
It is important that dissociation be carried out gently to minimize damage to the cells. It is preferred to dissociate organoids into cell clusters rather than single cells to promote better cell survival.
9. Centrifuge at 100 × g for 5 min at room temperature. Transfer supernatant to a new 50-ml tube while keeping the pellet.
10. Centrifuge the supernatant at 300 × g for 3 min at room temperature. Transfer supernatant to a new 50-ml tube while keeping the second pellet.
11. Centrifuge the supernatant at 1000 × g for 3 min at room temperature. Discard supernatant and keep the third pellet.
12. Combine the three pellets and resuspend in cerebral organoid medium (1 ml per organoid transferred in step 5).
Plate cerebral organoids 13. Aspirate excess medium from the Matrigel-coated plates and add 2 ml organoid medium to each well.
14. Using a 1-ml pipet, slowly spread 0.5 ml organoid suspension into each well and place plates in a 37°C incubator.
15. After 12-18 hr, replace medium by carefully removing half of the medium with a 1-ml pipet and slowly adding the same amount of fresh medium dropwise into each well.
16. Culture for 6 more days, changing half of the medium every 2-3 days.
During this time, the cells will regrow their processes and reestablish cellular interactions ( Fig. 1D ).
BASIC PROTOCOL 2
VIRAL INFECTION AND SAMPLE PREPARATION FOR FACS
This protocol describes how to prepare viral stocks, infect cerebral organoid cultures, and subsequently prepare infected cultures for FACS (Fig. 2) . The main protocol describes infection with a replicating virus (Zika). Infection with a single-cycle lentiviral reporter virus encoding GFP under the control of a CMV promoter in position of its envelope (env-defective HIV) and pseudotyped with the VSV-G envelope is described below (see Alternate Protocol). The env-defective HIV virus was generated by cloning the CMV EGFP expression cassette into the ENV position of the virus, while preserving the remaining full length with intact gag/pol and accessory proteins. This insertion restricts the virus to a single round of infection, since HIV virus particles defective for the envelope gene are generated.
Materials
VERO cells (ATCC CCL-81)
Vero cell culture medium (see recipe) Zika virus strain, e.g., Uganda 1947 (MR 766, ATCC 1838 15. Stain cells for 5 min with 2 ml per well fresh crystal violet staining solution for clear visualization of plaques. Figure 2B shows an example of a plaque assay after crystal violet staining.
Infect cerebral organoid cultures
16. Approximately 1 hr before infection, remove half of the medium from cerebral organoid cultures using a 1-ml pipet and replace with cerebral organoid medium supplemented with penicillin/streptomycin (1:50 dilution). Return to the 37°C incubator.
17. Thaw the appropriate amount of virus and control supernatant on ice. Using a 20-µl pipet, drip 5-20 µl virus or control supernatant (equaling the desired MOI) into the appropriate wells in a cross pattern to enhance spread throughout the whole well.
In order not to harm the axonal and dendritic cell connections, it is recommended not to shake the tissue culture plates to spread the virus.
18. Return the culture to the 37°C incubator for 72 hr. 23. Transfer cells to 50-ml tubes containing 3 ml DMEM/F12 medium for every well that is collected. Wash each well one time with 1 ml DMEM/F12 to collect any remaining cells.
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24. Centrifuge at 450 × g for 10 min at room temperature. Remove supernatant and gently resuspend cells in 5 ml FACS buffer.
Washing volumes are anticipated on cell pellets derived from approximately two to four plates.
25. Centrifuge at 450 × g for 5 min at room temperature. Remove supernatant and gently resuspend cells in 1 ml FACS buffer. Transfer to 1.5-ml microcentrifuge tubes.
26. Prepare 200 µl per sample of cell surface marker antibody mixture by adding the appropriate concentrations of fluorophore-conjugated antibodies for CD15, CD24, CD44, CD184, and CD271 to FACS buffer.
See Table 1 for antibody conjugates and dilutions used for flow cytometry and FACS.
27. Centrifuge cells at 450 × g for 5 min at room temperature. Remove supernatant, gently resuspend cells in 200 µl antibody mixture, and incubate 45 min in the dark at room temperature.
Since fluorophores are light sensitive, exposure of samples to light should be avoided from this step on.
28. Wash cells by adding 500 µl FACS buffer, centrifuging at 450 × g for 5 min at room temperature, removing the supernatant, and gently resuspending the cells in 500 µl FACS buffer.
29. Centrifuge at 450 × g for 5 min at room temperature, remove supernatant, and gently resuspend cells in 2% PFA (1:1 dilution of 4% PFA in DPBS). Incubate 5 min in the dark at room temperature.
30. Centrifuge at 450 × g for 5 min at room temperature, remove supernatant, and gently resuspend cells in 500 µl PermWash buffer. Repeat.
31. Centrifuge at 450 × g for 5 min at room temperature, remove supernatant, and gently resuspend cells in 200 µl PermWash buffer supplemented with antibody against ZIKV (fluorophore-conjugated anti-E-antigen, 4G2, Table 1 ). Incubate 1 hr in the dark at room temperature.
32. Centrifuge at 450 × g for 5 min at room temperature, remove supernatant, and gently wash cells with 500 µl PermWash buffer. Repeat at least once.
33. Centrifuge at 450 × g for 5 min at room temperature, remove supernatant, and gently resuspend cells in 1 ml FACS buffer. Place samples on ice and shield from light for transportation to the flow cytometer.
BASIC PROTOCOL 3
FLUORESCENCE-ASSISTED CELL SORTING
This protocol describes how to set the compensation parameters for multicolor FACS and set the appropriate gates to separate the cerebral organoid-derived cells by cell type (neurons, neural progenitors, and astrocytes) and infection based on their fluorescent labeling.
Materials
Fluorophore-conjugated antibodies (see Table 1 
Prepare compensation beads and determine sorter settings
1. Make single-stain controls for every antibody used. Vortex compensation beads for 5 min before use. To 1 drop of compensation beads from the dispenser bottle, add the same amount of conjugated antibody (or less) as used for staining one cell sample. For dilutions of conjugated antibodies, see Table 1 .
Binding of antibodies to compensation beads does not rely on the antibody's specificity or affinity, and therefore less antibody than required for staining one cell sample can be used. This is especially recommended when background staining of the negative bead population is too high. According to the manufacturer, 0.125 mg or less of staining antibody can be used with the compensation beads if 0.03-1 mg of antibody is used to stain one cell sample.
5. Analyze all single-stain controls to ensure that the positive peak for every antibodyfluorophore is on scale. Change PMT voltage, if necessary. Try to have a maximum spread between the positive and negative peaks for every control.
6. Once optimal PMT voltages for all channels are determined, run all single-stain controls again and record all data for compensation setup. Do not change PMT voltages anymore at this point.
If you need to change PMT voltages later, you will have to rerun all single-stain controls again with the adjusted PMT voltages.
7. Calculate the compensation matrix using the software provided with the flow cytometer (FACSDiva). , set gates, and sort Figure 2D .
Prepare samples
Illustration of infection and non-infection gates is shown in
Cells can be sorted first for cell type or infection depending on personal preference. If it is necessary to concentrate the cells after the first sorting round, centrifuge the samples at 450 × g and resuspend in FACS buffer.
10. Sort the different cell types (astrocytes, neural progenitor cells, neurons) from viruspositive and virus-negative cells using the gating scheme below and in Figure 2C .
a. Apply gates for CD271 and CD44 first. b. Gate CD271 − CD44 + cells for CD184+ to obtain cells with the astrocyte marker signature. c. Gate CD271 − CD44 − cells for CD184, CD24, and CD15 to separate neural progenitor cells (CD271 − CD44 − CD184 + CD24 + ) and neurons (CD271 − CD44 − CD184 − CD24 + CD15 low ).
11. Collect cells in three 5-ml FACS tubes with sorting efficiency of 90% or higher. Transfer cells to 15-ml Falcon tubes for further downstream applications.
Process samples for downstream applications
12. Centrifuge sorted cells at 450 × g for 10 min at 4°C. Keep on ice and remove supernatant without disturbing the pellet.
13. Directly add lysis buffer to the pellet for downstream DNA or RNA extraction or store cells at -80°C until further use. Figure 3A .
Examples of Zika virus infection rates per cell type are shown in
ALTERNATE PROTOCOL
SORTING OF PSEUDOTYPED HIV-INFECTED CEREBRAL ORGANOID CULTURES
To illustrate adaptation of the protocol to any virus that infects human neuronal cells, this protocol describes flow cytometry after infection with a single-cycle HIV lentiviral reporter virus. HIV1 lacking a functional Env gene and expressing a GFP reporter gene under the control of a CMV promoter was pseudotyped with the vesicular stomatitis virus (VSV-G) envelope glycoprotein to mediate cell entry but limit replication to a single round. The flow cytometry plots in Figure 3B show expression of the CMV promoterdriven GFP reporter gene in neural progenitors, neurons, and astrocytes, indicating that lentiviral integration is supported in these cell types.
CAUTION: Appropriate biosafety precautions including standard operating procedures for work with lentiviruses need to be implemented prior to work with lentiviruses. The described experiments were conducted in a BSL2+ facility by trained personnel.
Materials
HEK293T cells (ATCC CRL-3216) HEK293T cell culture medium (see recipe) Plasmids: molecular clone HIV R7/3 env CMV-EGFP, pHCMV-G coding for the G glycoprotein of VSV-G (Lloyd, Ng, Muesing, Simon, & Mulder, 2007) 
COMMENTARY
Background Information
The human brain is unique in its structure and functionality compared to other mammals. To circumvent the limitations of animal models, ample effort has been made to establish human cell-based models to study brain development, function, and disorders. Preceded by many protocols describing the generation of neural rosettes, neural progenitors, and different types of mature neuronal cells, the most comprehensive model resembling the human brain to date is the human stem cell-derived cerebral organoid model, which generates three-dimensional brain-like tissues in vitro that mimic not only the diversity of neuronal cell types but also the structure and cellular interactions typical of human brain tissue. The fact that cell development is similar to that in the in vivo environment, allowing establishment of heterotypical neuronal interactions, distinguishes this model from the direct differentiation of human stem cells into one specific neural cell type.
Challenges in studying these more complex multicellular tissues include potentially higher variability and increased complexity of data analyses. To facilitate the analysis of defined cell types in complex brain organoids upon virus infection, we developed a FACSbased protocol. FACS has been proven useful for sorting neuronal cells from adult rat brains and for distinguishing cell populations during neural induction of human embryonic stem cells (Yuan et al., 2011) . Choosing FACS over microscopy-based cell identification not only reduces output quantification errors, but also expands choices for downstream analyses of the identified cells. In this protocol, we use six-color cell sorting, which leaves the option to include more colors if the FACS/flow cytometer laser and filter setup allow for it. For example, inclusion of a viability dye to separate live from dead cells could reduce noise and improve separation of cell populations. However, one should be cautious about interference of the dead cell reagents with further downstream processing. The protocol we describe includes cell fixation either to allow intracellular staining of viral proteins and/or as a safety measure. Although not tested by 
Critical Parameters and Troubleshooting
The protocol includes three critical stages: preparing organoid cultures for optimal infection, obtaining well-prepared virus stocks, and sorting of immunostained cell samples. Due to the advanced-level sorting with at least six markers, guidance or assistance from a FACS specialist might be required for users who do not have advanced FACS skills. A guide to common problems with possible causes and solutions is summarized in Table 2 .
Anticipated Results
In a typical experiment, starting from ß15 organoids seeded in four 6-well plates, with an overall infection efficiency of 15%, one can expect to obtain 20,000 to 200,000 cells per group. For downstream applications, we have successfully extracted DNA suitable for bisulfite sequencing, or RNA suitable for whole transcriptome amplification and subsequent qRT-PCR from samples as low as ß4000 cells (Janssens et al., 2018) .
Time Considerations
The protocol starts from mature organoids, which will take up to 12 weeks to develop. Growing a virus stock and performing plaque assays usually takes 5 days. Preparing the infected organoid culture will take 10 days. The last day of the protocol, which includes cell collection, immunostaining, and FACS, should be anticipated to be labor intensive and may take up to 10 hr. It is therefore recommended to split some of the tasks between two people to lower the work load and reduce the time spent between collection and final freezing of the cells.
